Rodríguez Vicente Ana E, Herrero Cervera Maria José, Bernal María Luisa, Rojas Luis, Peiró Ana M
Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-USAL-CSIC, University Hospital of Salamanca, Salamanca, Spain.
Pharmacology Department, Faculty of Medicine, Universidad Valencia and Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Drug Metab Pers Ther. 2018 Dec 19;33(4):159-163. doi: 10.1515/dmpt-2018-0017.
Research and innovation in personalized medicine (PM) are extensive and expanding, with several pharmacogenetic/pharmacogenomic (PGx) testing options currently available for a wide range of health problems. However, PGx-guided therapy faces many barriers to full integration into clinical practice and acceptance by practitioner/patient: utilization and uptake by payers in real-world practice are being discussed, and the criteria to guide clinicians and policy makers in PGx test selection are not fully incorporated. This review focuses on the advances of pharmacogenomics to individualize treatments, the relationship between pharmacogenetics and pharmacometabolomics, the new paradigm of the Big Data, the needs and barriers facing PGx clinical application and the situation of PGx testing in health national services. It is based on lectures presented by speakers of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) Fourth Conference, held in Catania, October 4th, 2017.
个性化医疗（PM）领域的研究与创新广泛且不断扩展，目前针对多种健康问题有多种药物遗传学/药物基因组学（PGx）检测选项。然而，PGx 指导的治疗在全面融入临床实践并被从业者/患者接受方面面临诸多障碍：现实世界中支付方对其利用和采用情况正在讨论中，且指导临床医生和政策制定者进行 PGx 检测选择的标准尚未完全纳入。本综述聚焦于药物基因组学在个体化治疗方面的进展、药物遗传学与药物代谢组学之间的关系、大数据的新范式、PGx 临床应用面临的需求和障碍以及 PGx 检测在国家卫生服务中的情况。它基于 2017 年 10 月 4 日在卡塔尼亚举行的欧洲药物基因组学与个性化治疗学会（ESPT）第四届会议演讲者的讲座内容。
